Compounds and methods for treating addiction and related disorders

Patent metadata

Field	Value
Publication number	US-11839615-B2
Application number	US-201916968287-A
Country	US
Kind code	B2
Filing date	Feb 8, 2019
Priority date	Feb 9, 2018
Publication date	Dec 12, 2023
Grant date	Dec 12, 2023

Abstract

The present invention relates to adenosine receptor agonist compounds and methods of use thereof for treatment of certain disorders and conditions, for example an addiction or compulsive disorder. Exemplary compounds for use in disclosed methods include:and pharmaceutically acceptable salts thereof.

First claim

We claim:

1. A method of treating or promoting recovery from an addiction, addictive behavior, behavioral addiction, brain reward system disorder, compulsive disorder, or related condition, or treating relapse of an addiction or addictive behavior, comprising administering to a subject in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.

2. A method of treating or promoting recovery from withdrawal caused by addiction to a substance or drug having abuse potential, comprising administering to a subject in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The method of claim 2 , wherein the addiction is to a substance or drug having abuse potential selected from alcohol, nicotine, a narcotic, a prescription drug, and a recreational drug.

6. The method of claim 2 , wherein the substance or drug having abuse potential is selected from a stimulant, a depressant, a cannabinoid agonist, and an opioid agonist.

7. The method of claim 2 , wherein the substance or drug having abuse potential is selected from heroin, cocaine, alcohol, nicotine, an inhalant, a barbiturate, a benzodiazepine, a prescription opioid agonist analgesic, and an amphetamine; or an analogue, salt, composition, or a combination thereof.

8. The method of claim 2 , wherein the substance or drug having abuse potential is selected from alcohol, nicotine, heroin, cocaine, tetrahydrocannabinol (THC), amobarbital, allobarbital, aprobarbital, alphenal, barbital, brallobarbital, pentobarbital, phenobarbital, secobarbital, mephobarbital, butabarbital, tuinal, diazepam (Valium), alprazolam, lorazepam, clonazepam, zolpidem, bupropion, cathinone, MDMA, amphetamine, methamphetamine, dextroamphetamine, methylphenidate, opium, morphine, oxycodone, codeine, methadone, meperidine, oxymorphone, hydrocodone, tramadol, carfentanil, hydromorphone, and fentanyl; or a pharmaceutically acceptable salt or analogue thereof; or a combination thereof.

9. The method of claim 1 , wherein the subject has an alcohol or nicotine addiction.

10. The method of claim 1 , wherein the subject is a polydrug abuser.

11. The method of claim 1 , wherein the method at least partially reverses loss of glutamate uptake into astrocytes caused by the addiction.

12. The method of claim 1 , wherein the method increases energy metabolism mediated by astrocytes, glia, microglia, neurons, endothelium cells, or other cells of the brain and/or central nervous system (CNS).

13. The method of claim 1 , wherein the method treats a relapse of an addiction or addictive behavior in the subject.

14. The method of claim 1 , wherein the method decreases withdrawal symptoms in an addicted individual in withdrawal.

15. A method of ameliorating, treating, or promoting recovery from an addictive behavior, behavioral addiction, brain reward system disorder, compulsive disorder, or related condition, comprising administering to a subject in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , further comprising co-administering a second drug for treating withdrawal.

17. The method of claim 15 , wherein the addictive behavior, behavioral addiction, brain reward system disorder, compulsive disorder, or related condition is obsessive-compulsive disorder (OCD), Tourette syndrome, trichotillomania, anorexia, bulimia, anxiety disorder, psychosis, or post-traumatic stress disorder.

18. The method of claim 15 , wherein the addictive behavior, behavioral addiction, brain reward system disorder, compulsive disorder, or related condition is selected from gambling addiction, sex addiction, pornography addiction, an eating disorder, spending addiction, rage/anger, workaholism, exercise addiction, a risk-taking addiction, perfectionism, internet or video game addiction, or compulsive use of an electronic device.

Assignees

• Astrocyte Pharmaceuticals Inc
• Univ Texas

Inventors

• Korinek William S
• Liston Theodore E
• Lechleiter James D
• Beckstead Michael

Classifications

• H03K17/785

  controlling field-effect transistor switches · CPC title

• H02K21/046

  with rotating permanent magnets and stationary field winding · CPC title

• C07D473/40

  with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6 · CPC title

• A61P25/30

  for treating abuse or dependence · CPC title

• H02K11/33

  Drive circuits, e.g. power electronics (H02K11/38 takes precedence) · CPC title